Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has updated investors on the PANCOSIL clinical trial.
The Netherlands-based investigator-initiated clinical trial is being conducted at AMC Medical Centre in Amsterdam in collaboration with OncoSil Medical.
The PANCOSIL Trial is designed to assess the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer.
The trial aims to treat 20 patients with the OncoSil device through percutaneous application.
The company said the fifth patient in the trial received treatment on 28 May.
The company said the next step in the trial involves a protocol amendment to remove the requirement for mandatory general anesthesia. It said the amendment aims to allow treatment under conscious sedation, subject to approval from the ethics committee. The proposed change is expected to enhance patient comfort and expedite patient recruitment into the trial.
